vascular endothelial growth factor

(redirected from Pazopanib)
Also found in: Dictionary, Medical.

vascular endothelial growth factor

[¦vas·kyə·lər ‚en·dō¦thē·lē·əl ′grōth ‚fak·tər]
(medicine)
A soluble factor that acts through specific cell-surface receptors on endothelial cells to critically regulate vasculogenesis.
References in periodicals archive ?
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
With pazopanib, patients have a chance to control their kidney cancer while maintaining quality of life and avoiding some of the side effects, which can be severe, that can occur with current treatments.
Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma.
Everolimus, golimumab combined with methotrexate, pazopanib, and pitavastatin, should be classified as contraindicated.
Specific topics include the discovery of Pazopanib as a pan-vascular endothelial growth factor kinase inhibitor, the structure-based design and characterization of Axitinib; allosteric MEK inhibitors, PHA-793958, GSK461364 as a polo-like kinase-one inhibitor for treating cancer, the practical use of computational chemistry in kinase drug discovery, and approaches to kinase homology modeling.
Glaxo's pazopanib may be "associated with a significant risk" of severe liver injury in patients with advanced renal cell carcinoma, the most-common form of kidney cancer, agency staff said in a review posted last week on the agency's Web site.
The company announced positive results for two of its pipeline drugs Tykerb and pazopanib.
Angiogenesis Pazopanib (Glaxo- Bevacizumab (Avastin[R] inhibitors SmithKline) Genentech, Inc.
The treatments are cervarix, pazopanib, promacta, rezonic and of atumumab.
Furthermore, 85 percent of retinal specialists report aided awareness of aflibercept, significantly more than those aware of other surveyed products in development for wet AMD, including Ophthotech's Fovista, GlaxoSmithKline's pazopanib and Ohr Pharmaceutical's squalamine.
Trial patients are randomized 1:1 to be treated with aldoxorubicin or the investigator's choice of an approved chemotherapeutic regimen, including doxorubicin, ifosfamide, dacarbazine, pazopanib (Votrient), or gemcitabine plus docetaxel.
3) There were a total of 134 patients included in the study, of whom 58 received first-line sunitinib, 62 received another first-line anti-VEGF therapy (sorafenib [n = 23], bevacizumab [n = 16], pazopanib [n = 13], tivozanib [n = 5], axitinib [n = 3], and other [n = 2]) and 14 received a first-line cytokine-based therapy.